Information  X 
Enter a valid email address

Novacyt S.A. (NCYT)

  Print   

Tuesday 19 October, 2021

Novacyt S.A.

Results of annual general meeting

RNS Number : 5744P
Novacyt S.A.
19 October 2021
 

Novacyt S.A.

 

("Novacyt" or the "Company")

 

RESULTS OF ANNUAL GENERAL MEETING

 

Paris, France and Camberley, UK - 19 October 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that its Annual General Meeting (AGM), comprising ordinary and extraordinary general meetings, was held yesterday afternoon.

 

The Company is pleased to report that all resolutions proposed to the shareholders were duly passed. The results of the AGM voting will be available on the Company's website shortly.

 

In addition, as previously announced on 29 July 2021, David Allmond became Chief Executive Officer and a member of the Board of Directors of Novacyt on 18 October 2021.

 

- End -

 

For further information, please refer to   www.novacyt.com   or contact:

 

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

[email protected] / [email protected]  

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

[email protected] / [email protected]  

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

[email protected]  

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests.  Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGEKLFFFBLFFBL

a d v e r t i s e m e n t